Member Info for Willowman19

What would happen to the share price should they be a merger or T/O.

Eddo12, what I did was contact Sati by email.
The admin is a lovely lady who will respond to you.
I also signed up for their email alerts.

Regards WM19

Prophet52, hello.

You could have done your due dilligence on the company, in the time you've been asking for info.
Not having a go just saying.

Dear ......

Thank you for your email and your continued support.

Whilst the announcement was made regarding Dan, it is very much business and
usual for the Company and since the release of our Busines Update in May
2020, there is nothing more to update the market on.

As you will have seen in the latest press release, Dr Chris Blackwell is now
Executive Chairman and, along with an experienced and strong team, he is
committed to continuing with an unchanged objective for the success of the
Company.

Looking ahead; in July, we will be announcing Preliminary Results for the
period year ended 31 March 2020, and a date will be set for this and
communicated in due course.

Kind regards.

Fleur Wood
Investor Relations

Email: fleur.wood@nuformix.com

Let investor relations do their job.
I've emailed Fleur asking for a update on where things are at. Not a big ask.

https://ir.vistagen.com/press-releases/detail/140/vistagen-and-nuformix-announce-agreement-to-develop-novel

PRESS RELEASE ACCESSWIRE
Mar. 2, 2020, 04:45 AM
Related Stocks

StillCanna 0.07-0.01 (-7.53%) 4/17/2020 StillCanna Inc Registered Shs Disclaimer Get real-time StillCanna charts here >>
VANCOUVER, BC / ACCESSWIRE / March 2, 2020 / Stillcanna Inc. (OTC:SCNNF) (CSE:STIL) (FRANKFURT:A2PEWA) ("STIL" or the "Company") Stillcanna has obtained all approvals required to begin commercial operations at its ORIGIN extraction facility in Romania and the Company is pleased to announce the appointment of Mr. Paul van Issum as President of European Operations, effective immediately.

ORIGIN, a joint venture between Stillcanna and Dragonfly Biosciences Ltd. of the UK has received formal endorsement from the Romanian Environmental Protection Agency and Emergency Services Unit. The facility has also received its final operational permit from the town hall of Bailesti Romania. As the operational phase is implemented over the next quarter the Company is expected to begin hiring additional staff and commencing production trials.

Previously, Mr. van Issum was working directly with Mr. Dussault and the Stillcanna management team for more than a year, most recently as a consultant spearheading ORIGIN‘s permit and approval process with various regional and national authorities in Romania. Prior to this, he enjoyed an extensive career as a senior equity capital markets banker. Mr. van Issum is now responsible for the day-to-day operations for all of Stillcanna's European operations.

"With the approvals for our Romanian-based ORIGIN facility in hand, this is the right time to introduce Paul van Issum as our President of European Operations," commented Jason Dussault, CEO Stillcanna. "Paul's efforts in navigating the legal and regulatory frameworks in Romania are a major reason we received the necessary approvals to establish the first fully licensed purpose-built CBD extraction facility in Romania. We have full confidence in Paul's ability to push Stillcanna towards profitability and long-term success moving forward."

"Stillcanna's operations in Poland and Romania leave the Company uniquely positioned in this developing European CBD market," said Mr. van Issum. "I look forward to working with the Stillcanna team to transform this great opportunity into a profitable reality."

StillCanna Begins Hemp Initiative in Poland

Vancouver, British Columbia--(Newsfile Corp. - April 30, 2019) - StillCanna Inc. (CSE: STIL) ("STIL" or the "Company") is pleased to announce it has begun its agricultural initiatives in Poland to farm over 1,500 hectares of its propriety high CBD content hemp varietal.

StillCanna has ordered and anticipates delivery in July of special harvesters and conveyors with proprietary dryers to make the harvest easy and efficient. The high-tech equipment is capable of speeds up to 15km per hour with a special four and a half meter wide cutting device. It's estimated that the Company's 2019 harvest will produce over 16 million grams of pure CBD. As our proprietary strain of hemp has a gestation period of 45 days, the Company is considering planting two crops on a number of its properties to increase its CBD production capabilities for 2020.

The Company anticipates breaking ground in May for its new CBD refinement facility in Poland, which is expected to cost approximately $6 million to complete its development. The facility is designed to have the capacity to initially produce up to 40 million grams of CBD annually with the ability to further build out the facility to increase production as necessary.

"Spring is an exciting time for global agriculture and StillCanna," explained Jason Dussault, Chief Executive Officer of StillCanna. "The expansion of our EU footprint into Poland is yet another milestone in the implementation of our business initiatives. With over 20 years experience in hemp cultivation, we look forward to meeting the ever increasing demand for quality CBD from our fields and facilities."

The Company also announces that it has engaged Native Ads Inc. to provide and manage a comprehensive digital media marketing campaign for the Company.

The Company has entered into an eight week programmatic digital advertising campaign for an approximate cost of one hundred thousand dollars for digital advertising, paid distribution, media buying and content creation. Neither Native Ads nor any of its directors and officers own any securities of the Company.

StillCanna has large cultivation and extraction assets and is on the cusp of significant revenue growth: It is one of Europe’s largest CBD companies with 1500 hectares of hemp cultivated in Poland in 2019 with this expected to grow to 3000Ha in 2020. It has two large extraction facilities based on a proprietary closed loop ethanol-based design with combined capacity to produce up to 29 tonnes of CBD isolate pa. Its wholly owned extraction in Poland has recently started production with the group recording its first revenues in the quarter to January 2020, and its JV facility with DragonFly in Romania recently received its final operating permit and awaiting the lifting of the COVID-19 lockdown before resuming commissioning.
It complements Sativa’s leading position in UK distribution and branding and puts the group in a strong position with regards to Novel Food compliance: both companies share a culture of compliance and the resulting vertically integrated entity will be able to provide full traceability of testing and compliance from seed to sale. Both were already engaged in the process of achieving UK and European FSA Novel food compliance prior to the UK March 2021 deadline. We believe success in the UK by Sativa’s Goodbody brands is likely to help generate demand in other jurisdictions, as well as for wholesale and white label CBD supply.
Attractive deal structure for both sets of shareholders: Based on the current share prices, the resulting group will be 65% owned by Sativa shareholders with Sativa not just bringing branding and distribution in the most important EU CBD market, but also a cannabinoid testing laboratory, as well as medicinal and veterinary cannabinoid asset development. For Sativa, StillCanna brings compliant EU cannabinoid supply at scale, as well as balance sheet strength which, combined with potentially significant third-party CBD sales this year, should see the group well through COVID-19 but potentially also be able to trade to self-sufficiency without further equity funding.

StillCanna has raised over C$30m in equity financing, including a C$24m raise in April 2019. In its most recent financials, the three months ended 31 January 2020, it recorded its first quarterly revenues C$0.23m (from Nexus) and an operating loss of C$2.06m. It reported cash and equivalents of C$6.72m, $1.23m in inventories and is debt free apart from C$0.20m of leases. This therefore gives it little more than 9 months of cash runway at that cash burn rate. As such, its financial statement included a statement that there is material uncertainty that casts significant doubt about the Company’s ability to continue as a going concern.
That said, with the Nexus facility now operational and PES expected to start production in the coming months, and with significant capacity in cultivation and extraction, the company looks like it could trade its way to self-sufficiency within the next six months and with its current cash position. This potentially could then provide headroom in funding to support the combinedgroup with Sativa, especially if cost synergies can be achieved through the combination of the two businesses.
A back of the envelope calculation suggests that the 1500 Ha cultivated by StillCanna in 2019 would theoretically hold over 7 tonnes of CBD (using a conservative CBD yield in flower of c3.5%) which could be extracted in six months. With a wholesale value of over €5/g for traceable compliant EU CBD distillate and isolate, this supply could deliver revenues over €35m this year. Additional revenues could be made by StillCanna by toll processing third-party crop using spare capacity in its Nexus facility as well as from the Premium Extraction Services JV with DragonFly who also has considerable hemp flower in stock to process once fully operational

I'm quite excited about the potential takeover.
We will be growing hemp in Romainia and Poland and selling it.
We have what Sativa group has now plus what stillcanna are doing. Hemp is becoming popular, used for biomass and the CBD which is used general sales and Pharma grade. Medical cannabis is in there which is going to take off, as it does what it says on the tin with few side effects. The world is turning away from opiates and I believe CBD and other molecules from the plant will become very popular medicines, among other things. The world will be turning away from plastics and hemp can be used like plastic, , imo dyor
I believe this could do very well over the coming years, and that's why I'm invested and will be building a bigger position should the takeover happen.

What are the medical benefits of cannabinoids?

ANSWER

Cannabinoids -- the active chemicals in medical marijuana -- are similar to chemicals the body makes that are involved in appetite, memory, movement, and pain.

Research suggests cannabinoids might:

Reduce anxiety
Reduce inflammation and relieve pain
Control nausea and vomiting caused by chemotherapy
Kill cancer cells and slow tumor growth
Relax tight muscles in people with multiple sclerosis
Stimulate appetite and improve weight gain in people with cancer and AIDS

Imagine a cbd inhaled therapy using co crystal tech. Imagine how much good we could do with this medicine to treat people with painful joint conditions.
This deal with Ebers has so much potential, literately.
There not much online either about Ebers, I have been looking.
This deal has the potential to make NFX share holders lots of money. Imo dyor

Another piece of the pie

I'm waiting for edibles to become mainstream in the uk. I'm invested in uk CBD and Medical cannabis and recreation when it's legalised. I believe this will be huge in a few years.

Imagine NFX/ Ebers co crystal cbd for epilepsy using a nebuliser. Improve what's already been done with GW Pharma. There lots of different molecules in cannabis Sativa that have the potential to do something really amazing in medicine.

Cannabis Sativa rocks as far as I'm concerned.

Building with hemp products, hemp concrete, roof tiles the whole shebang. Hemp plastics etc. Hemp car batteries which I've read are more efficient that existing batteries.
hemp is being grown in Romainia as well as other European countries to satisfy the demand for hemp and hemp products., bio fuel, beauty products, Pharma grade cbd which is amazing as an anti inflammatory. I believe the potential is huge, Imo dyor, that's why I'm invested.

Hello Stevebuy, I'm holding for a trade sale and I have a similar amount of shares as yourself. I've sat patiently since last May and will hold for as long as it takes.
I believe in NFX and its tech.

· All options and warrants in Sativa are expected to be exchanged for options and warrants in StillCanna using the same ratio.

· If the transaction were to be carried out based on the exchange ratio referred to above, Sativa shareholders (as at today's date) would hold approximately 65% of all StillCanna shares following completion, including all option and warrant instruments outstanding.

· It is envisaged that the transaction would be achieved through a UK Scheme of Arrangement under Part 26 of the UK Companies Act 2006.

The LOI provides for an exclusivity period, allowing the Company to conduct due diligence on StillCanna. StillCanna will not pursue any alternative transaction to the proposed acquisition of Sativa during the exclusivity period.

Other than in a limited number of circumstances, if StillCanna does not proceed to make an offer to acquire the shares of the Company pursuant to the LOI, StillCanna will be required to pay a break fee to Sativa at the greater of either, £1,000,000, or if StillCanna enters into an Alternative Transaction, 25% of the value paid by StillCanna or for StillCanna's securities or assets (as the case may be) in such alternative transaction. Discussions remain at a very early stage and accordingly there can be no certainty that a firm offer will be made.

· StillCanna wishes to explore a potential transaction where StillCanna will acquire the entire issued share capital of Sativa in consideration for which StillCanna will issue StillCanna Shares to the Sativa shareholders on the basis of 0.33651 StillCanna Shares for each Sativa share in issue.

What do people think about the Ebers deal, and the potential there.
This is just my opinion of what could be.
Cannabis is an amazing drug. We all know about its effects on epilepsy in children.
A company who has moved onto Nasdaq, GW Pharma is doing quite well with their cannabis based drugs. Say we do the same using co crystal tech. This has the potential to be huge for NFX.
Has anyone else got an opinion, please share.

Hello, I have worked in mental health for over a decade and have come across many people who use cannabis to treat bi polar symptoms. Sati are well positioned for when cannabis becomes mainstream NHS and eventually general sales.
Slowly but surely.

Hello Guys, this is my first post.
Cannabis related products.
I have interests in Canadian pot both recreational and medical, CBD too.
I suffer from pain in my joints and have chosen to use cannabis to ease the pain.
Within 10 minutes of having a joint, pain in my joints has gone, I can walk and operate pain free. And that's just thc in the Cannabix Sativa plant. This is going to go BOOM in the UK very soon.
I think cannabis is the best thing since sliced bread, IMO DYOR.
Pot is going to be massive in the uk within the next 5 to 10 years.
We have seen what it does to little kids with epilepsy, amazing.
I have to use a dealer to buy my medicine at £150 OZ. I would like to grow my own organic in the garden, but risk the police popping round.
I see very good results coming from the Nfx and Ebers dealings. This is only the start. U.K. Company's are growing weed and Kings College hospital are going to be starting trails with cannabis. DYOR
I see nurformix in the middle of all this too. Just my opinion.
As human beings it is in our genes to get out of our normal consciousness occasionally. The thing is to find the least harmful. Cannabis does it for me and many others. There is going to be a lot of money made from weed and related products and medicines in the world.
I'm learning every day about stocks and shares. I've only been into it a year, I'm a stocks and shares layman, so go easy.
I have been into Nfx since 3.2p, and average 6.4p I absolutely buzz when there's news on Nfx and there is uproar on this board. I see big things with NFX.
This is all my opinion, do your own research.